Recruiting
Chronic lymphocytic leukaemia recurrent+1
RecruitingRegistered drugNo placebo
A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment
Registered drugNo placebo
- Disease:Chronic lymphocytic leukaemia recurrentB-cell small lymphocytic lymphoma recurrent
- Substances:AcalabrutinibVenetoclax
Countries:
Austria
Austria- Participants:18–64 years · 65+ years
- Substances:Acalabrutinib
- Sponsor:AstraZeneca AB



